{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:54:41Z","timestamp":1787774081421,"version":"build-2784847793"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ejim.2018.09.005","type":"journal-article","created":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T00:07:40Z","timestamp":1538179660000},"page":"70-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Management of immune thrombocytopenia in elderly patients"],"prefix":"10.1016","volume":"58","author":[{"given":"Elisa","family":"Lucchini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Fanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichola","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2018.09.005_bb0005","series-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group standardization of terminology, definitions and outcome criteria in immune thrombocyt","first-page":"2386","volume":"vol. 113","author":"Rodeghiero","year":"2009"},{"key":"10.1016\/j.ejim.2018.09.005_bb0010","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMra010501","article-title":"Immune Thrombocytopenic Purpura","volume":"346","author":"Cines","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2018.09.005_bb0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1182\/asheducation.V2012.1.191.3798260","article-title":"How to approach thrombocytopenia","volume":"2012","author":"Stasi","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ejim.2018.09.005_bb0020","first-page":"636","article-title":"Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura","volume":"115","author":"Harrington","year":"1990","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.ejim.2018.09.005_bb0025","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2141.2009.07717.x","article-title":"Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and\/or decreased platelet production","volume":"146","author":"Nugent","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0030","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1182\/blood.V87.10.4245.bloodjournal87104245","article-title":"Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity","volume":"87","author":"Semple","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0035","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2003-07-2268","article-title":"Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response","volume":"103","author":"Panitsas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0040","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3324\/haematol.12889.","article-title":"Increased cytotoxic T-lymphocyte-mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies","volume":"93","author":"Zhao","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.ejim.2018.09.005_bb0045","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/nm921","article-title":"T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura","volume":"9","author":"Olsson","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.ejim.2018.09.005_bb0050","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0609.2006.00780.x","article-title":"Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura","volume":"78","author":"Liu","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0055","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2008-01-135335","article-title":"Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura","volume":"112","author":"Yu","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0060","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1182\/blood-2012-05-432575","article-title":"Defective regulatory B-cell compartment in patients with immune thrombocytopenia","volume":"120","author":"Li","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0065","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2008-02-139402","article-title":"Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1","volume":"112","author":"Olsson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0070","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1532\/IJH97.04168","article-title":"The effect of antiplatelet autoantibodies on megakaryocytopoiesis","volume":"81","author":"McMillan","year":"2005","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0075","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1046\/j.1365-2141.1996.d01-1702.x","article-title":"Circulating thrombopoietin level in chronic immune thrombocytopenic purpura","volume":"93","author":"Kosugi","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0080","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2141.2006.06024.x","article-title":"The pathogenesis of immune thrombocytopaenic purpura","volume":"133","author":"Cooper","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0085","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.autrev.2017.04.012","article-title":"Pathogenesis of immune thrombocytopenia","volume":"16","author":"Audia","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ejim.2018.09.005_bb0090","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminhematol.2008.12.005","article-title":"Pathobiology of secondary immune thrombocytopenia","volume":"46","author":"Cines","year":"2009","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0095","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/blood.V94.3.909.415k02_909_913","article-title":"The incidence of idiopathic thrombocytopenic purpura in adults increases with age","volume":"94","author":"Frederiksen","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0100","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1046\/j.1365-2141.2003.04547.x","article-title":"Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients","volume":"122","author":"Neylon","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0105","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2009.07615.x","article-title":"Epidemiology of immune thrombocytopenic purpura in the general practice research database","volume":"145","author":"Marieke Schoonen","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0110","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood-2014-05-578336","article-title":"Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France","volume":"124","author":"Moulis","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0115","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0002-9343(99)80342-8","article-title":"Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2018.09.005_bb0120","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0125","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjh.14515","article-title":"State of the art \u2013 how I manage immune thrombocytopenia","volume":"177","author":"Cooper","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0130","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminhematol.2008.12.006","article-title":"Therapeutic strategies for hepatitis- and other infection-related immune thrombocytopenias","volume":"46","author":"Stasi","year":"2009","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0135","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.3748\/wjg.v20.i10.2595","article-title":"Management of thrombocytopenia due to liver cirrhosis: a review","volume":"20","author":"Hayashi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0140","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0145","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.hoc.2009.08.008","article-title":"Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production","volume":"23","author":"McMillan","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ejim.2018.09.005_bb0150","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMra0902908","article-title":"Myelodysplastic syndromes","volume":"361","author":"Tefferi","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2018.09.005_bb0155","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0160","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/cncr.22602","article-title":"The incidence and impact of thrombocytopenia in myelodysplastic syndromes","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ejim.2018.09.005_bb0165","article-title":"Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia","volume":"1","author":"Waisbren","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0170","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/1042819031000063507","article-title":"Clinico-hematologic features of myelodysplastic syndrome presenting as isolated thrombocytopenia: an entity with a relatively favorable prognosis","volume":"44","author":"Sashida","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejim.2018.09.005_bb0175","series-title":"Transfusion medicine and hemostasis","first-page":"487","article-title":"Drug-induced thrombocytopenia","author":"Bennett","year":"2009"},{"key":"10.1016\/j.ejim.2018.09.005_bb0180","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood-2010-03-276691","article-title":"Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods","volume":"116","author":"Reese","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0185","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/ajh.23299","article-title":"Platelet count or bleeding as the outcome in ITP trials","volume":"87","author":"Arnold","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0190","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood.V77.1.31.31","article-title":"High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura","volume":"77","author":"Cortelazzo","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0195","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1001\/archinte.160.11.1630","article-title":"The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts","volume":"160","author":"Cohen","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2018.09.005_bb0200","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00277-012-1567-2","article-title":"Immune thrombocytopenia in the elderly: Clinical course in 525 patients from a single center in China","volume":"92","author":"Zhou","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0205","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3324\/haematol.2009.018390","article-title":"Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom general practice research database","volume":"95","author":"Sarpatwari","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.ejim.2018.09.005_bb0210","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1365-2141.2010.08418.x","article-title":"Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study","volume":"152","author":"Severinsen","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0215","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s12185-010-0636-3","article-title":"Comorbidities in patients with persistent or chronic immune thrombocytopenia","volume":"92","author":"Enger","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0220","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/jth.12636","article-title":"Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors","volume":"12","author":"Ruggeri","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2018.09.005_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2012.08.282","article-title":"Thrombosis in patients with primary chronic immune thrombocytopenia","volume":"130","author":"N\u00f8rgaard","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejim.2018.09.005_bb0230","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2007.02450.x","article-title":"Incidence and mortality of venous thrombosis: a population-based study","volume":"5","author":"Naess","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2018.09.005_bb0235","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.medcli.2011.11.023","article-title":"Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials","volume":"139","author":"Catal\u00e1-L\u00f3pez","year":"2012","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.ejim.2018.09.005_bb0240","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/ajh.24234","article-title":"Is ITP a thrombophilic disorder?","volume":"91","author":"Rodeghiero","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0245","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/bjh.14412","article-title":"Procoagulant profile in patients with immune thrombocytopenia","volume":"175","author":"\u00c1lvarez-Rom\u00e1n","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0250","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1160\/TH12-12-0941","article-title":"Red cell-derived microparticles (RMP) as haemostatic agent","volume":"110","author":"Jy","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2018.09.005_bb0255","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1160\/TH13-10-0873","article-title":"Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia","volume":"112","author":"Alvarez Rom\u00e1n","year":"2014","journal-title":"Thromb Haemost"},{"issue":"Suppl. 2","key":"10.1016\/j.ejim.2018.09.005_bb0260","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1093\/geronb\/gbu025","article-title":"Comorbidity and chronic conditions in the National Social Life, Health and Aging Project (NSHAP), Wave 2","volume":"69","author":"Vasilopoulos","year":"2014","journal-title":"J Gerontol B Psychol Sci Soc Sci"},{"key":"10.1016\/j.ejim.2018.09.005_bb0265","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1161\/CIRCULATIONAHA.106.653048","article-title":"Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation","volume":"115","author":"Hylek","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2018.09.005_bb0270","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","article-title":"Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data","volume":"374","author":"S\u00f8rensen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2018.09.005_bb0275","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1182\/blood-2010-10-312819","article-title":"Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study","volume":"117","author":"N\u00f8rgaard","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0280","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ajh.20992","article-title":"Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura","volume":"83","author":"McMillan","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0285","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3111\/13696998.2012.688902","article-title":"The burden of immune thrombocytopenia in adults: Evaluation of the thrombopoietin receptor agonist romiplostim","volume":"15","author":"Deuson","year":"2012","journal-title":"J Med Econ"},{"key":"10.1016\/j.ejim.2018.09.005_bb0290","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1185\/03007990802377461","article-title":"Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey","volume":"24","author":"Snyder","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejim.2018.09.005_bb0295","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2141.2008.07464.x","article-title":"Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials","volume":"144","author":"George","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0300","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/ajh.23163","article-title":"Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care","volume":"87","author":"Kuter","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(09)60402-5","article-title":"Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: A randomised, double-blind, placebo-controlled trial","volume":"373","author":"Bussel","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2018.09.005_bb0310","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/ajh.22170","article-title":"Characteristics and outcome of immune thrombocytopenia in elderly: results from a single center case-controlled study","volume":"86","author":"Michel","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0315","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ejim.2007.07.006","article-title":"Idiopathic thrombocytopenic purpura in elderly patients: a study of 47 cases from a single reference center","volume":"19","author":"Daou","year":"2008","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2018.09.005_bb0320","article-title":"Corticosteroid risk function of severe infection in primary immune thrombocytopenia adults. A nationwide nested case-control study","volume":"10","author":"G., M., A., P. & L., S","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2018.09.005_bb0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4081\/reumatismo.2016.870","article-title":"Guidelines for the diagnosis, prevention and management of osteoporosis","volume":"68","author":"M., R","year":"2016","journal-title":"Reumatismo"},{"key":"10.1016\/j.ejim.2018.09.005_bb0330","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-0609.2005.00602.x","article-title":"Idiopathic thrombocytopenic purpura (ITP) in the elderly: Clinical course in 178 patients","volume":"76","author":"Bizzoni","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0335","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1056\/NEJMoa030254","article-title":"Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone","volume":"349","author":"Cheng","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2018.09.005_bb0340","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1182\/blood-2005-12-015222","article-title":"Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience","volume":"109","author":"Mazzucconi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0345","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2352-3026(16)30109-0","article-title":"High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"3","author":"Mithoowani","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0350","article-title":"High-dose dexamethasone versus prednisone for treatment of adult immune thrombocytopenia: A prospective multicenter randomized trial","volume":"127","author":"Wei","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0355","first-page":"35","article-title":"Intravenous Immunoglobulin (IVIg) utilization in Immune Thrombocytopenia (ITP): a multi-center, retrospective review","volume":"2","author":"Hsia","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.ejim.2018.09.005_bb0360","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1517\/14740338.2010.484419","article-title":"Safety of intravenous immunoglobulin treatment","volume":"9","author":"Caress","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ejim.2018.09.005_bb0365","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1365-2133.2006.07390.x","article-title":"Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature","volume":"155","author":"Marie","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0370","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjh.14067","article-title":"How we manage immune thrombocytopenia in the elderly","volume":"173","author":"Mah\u00e9vas","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0375","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s12325-015-0251-z","article-title":"Current Management of Primary Immune Thrombocytopenia","volume":"32","author":"Provan","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.ejim.2018.09.005_bb0380","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1182\/blood.V95.8.2523","article-title":"Acute onset hemoglobinemia and\/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients","volume":"95","author":"Gaines","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0385","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/blood-2009-07-229815","article-title":"Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia","volume":"115","author":"Zaja","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0390","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1182\/blood-2012-09-455691","article-title":"Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia","volume":"121","author":"Gudbrandsdottir","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0395","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1182\/blood-2014-01-549360","article-title":"Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults","volume":"123","author":"G\u00f3mez-Almaguer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0400","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ajh.21060","article-title":"Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients","volume":"83","author":"Spahr","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0405","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3126\/kumj.v10i1.6922","article-title":"Severe immune thrombocytopenic purpura treated with plasma exchange","volume":"10","author":"Sigdel","year":"2012","journal-title":"Kathmandu Univ Med J"},{"key":"10.1016\/j.ejim.2018.09.005_bb0410","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/bjh.15090","article-title":"A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP","volume":"181","author":"Rodeghiero","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0415","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/ejh.12821","article-title":"Long-term results of splenectomy in adult chronic immune thrombocytopenia","volume":"98","author":"Guan","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0420","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3324\/haematol.2012.075648","article-title":"Splenectomy as a curative treatment for immune thrombocytopenia: A retrospective analysis of 233 patients with a minimum follow up of 10 years","volume":"98","author":"Vianelli","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ejim.2018.09.005_bb0425","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/ejh.12146","article-title":"Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia","volume":"91","author":"Gonzalez-Porras","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0430","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000442703","article-title":"Clinical outcome and predictive factors in the response to splenectomy in elderly patients with primary immune thrombocytopenia: A multicenter retrospective study","volume":"135","author":"Park","year":"2016","journal-title":"Acta Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0435","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00129689-200212000-00005","article-title":"Laparoscopic splenectomy for idiopathic thrombocytopenic purpura","volume":"12","author":"Delaitre","year":"2002","journal-title":"Surg Laparosc Endosc Percutan Tech"},{"key":"10.1016\/j.ejim.2018.09.005_bb0440","doi-asserted-by":"crossref","first-page":"E267","DOI":"10.1002\/ajh.24310","article-title":"Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years","volume":"91","author":"Palandri","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0445","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/ajh.20433","article-title":"Analysis of outcome of laparoscopic splenectomy for idiopathic thrombocytopenic purpura by platelet count","volume":"80","author":"Keidar","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0450","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/j.jss.2011.06.031","article-title":"Laparoscopic splenectomy for patients with immune thrombocytopenia and very low platelet count: is platelet transfusion necessary?","volume":"170","author":"Chen","year":"2011","journal-title":"J Surg Res"},{"key":"10.1016\/j.ejim.2018.09.005_bb0455","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1182\/blood-2012-12-467068","article-title":"Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia","volume":"121","author":"Boyle","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0460","article-title":"Long-term complications of splenectomy in adult immune thrombocytopenia","volume":"95","author":"Thai","year":"2016","journal-title":"Medicine (United States)"},{"key":"10.1016\/j.ejim.2018.09.005_bb0465","series-title":"Clinical infectious disease","first-page":"629","article-title":"Overwhelming postsplenectomy infection","author":"Lutwick","year":"2015"},{"key":"10.1016\/j.ejim.2018.09.005_bb0470","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2141.2010.08377.x","article-title":"Autologous 111In-labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP Registry","volume":"151","author":"Sarpatwari","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0475","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2014-06-582346","article-title":"Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients","volume":"124","author":"Khellaf","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0480","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-11-393975","article-title":"Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia","volume":"119","author":"Patel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0485","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ajh.21512","article-title":"Repeated courses of Rituximab in chronic ITP: three different regimens","volume":"84","author":"Hasan","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0490","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/ajh.24434","article-title":"Gender and duration of disease differentiate responses to rituximab\u2013dexamethasone therapy in adults with immune thrombocytopenia","volume":"91","author":"Chapin","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0495","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1600-0609.2010.01486.x","article-title":"Low-dose rituximab in adult patients with primary immune thrombocytopenia","volume":"85","author":"Zaja","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0500","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S2352-3026(15)00003-4","article-title":"Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"2","author":"Chugh","year":"2015","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ejim.2018.09.005_bb0505","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2013-04-494096","article-title":"The effect of rituximab on vaccine responses in patients with immune thrombocytopenia","volume":"122","author":"Nazi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0510","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00277-010-0962-9","article-title":"Hepatitis B reactivation induced by Rituximab maintenance therapy for lymphoma","volume":"90","author":"Cho","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0515","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","article-title":"Rituximab-associated infections","volume":"47","author":"Gea-Banacloche","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0520","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1053\/j.seminhematol.2010.01.009","article-title":"Rituximab-associated neutropenia","volume":"47","author":"Dunleavy","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0525","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the research on adverse drug events and reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0530","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: Final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0535","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bjh.12260","article-title":"Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: Safety and efficacy","volume":"161","author":"Kuter","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0540","article-title":"Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysish","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejim.2018.09.005_bb0545","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood-2008-04-150078","article-title":"Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP","volume":"113","author":"Bussel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.09.005_bb0550","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12185-015-1837-6","article-title":"Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim","volume":"102","author":"Cines","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0555","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000452992","article-title":"A 2-year, longitudinal, prospective study of the effects of eltrombopag on bone marrow in patients with chronic immune thrombocytopenia","volume":"137","author":"Brynes","year":"2017","journal-title":"Acta Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0560","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-016-2682-2","article-title":"Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia","volume":"95","author":"Janssens","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0565","first-page":"94","article-title":"Bone marrow fibrosis in immune thrombocytopenia (ITP) patients treated with thrombopoietin receptor agonists (TRA)-a single center long-term follow-up","volume":"336A","author":"Boiocchi","year":"2014","journal-title":"Lab. Investig."},{"key":"10.1016\/j.ejim.2018.09.005_bb0570","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1365-2141.2011.08845.x","article-title":"Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents","volume":"155","author":"Ghanima","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0575","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s00277-015-2485-x","article-title":"Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged \u226565 years with immune thrombocytopenia","volume":"94","author":"Michel","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0580","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/ejh.12807","article-title":"A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice","volume":"98","author":"Steurer","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0585","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/ejh.12725","article-title":"Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice","volume":"97","author":"Gonzalez-Lopez","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0590","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1179\/1607845415Y.0000000041","article-title":"Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim \u2020","volume":"21","author":"Bussel","year":"2016","journal-title":"Hematology"},{"key":"10.1016\/j.ejim.2018.09.005_bb0595","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1002\/ajh.23900","article-title":"Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia","volume":"90","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0600","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/ajh.24935","article-title":"Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: a retrospective collaborative survey from Italian hematology centers","volume":"93","author":"Cantoni","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0605","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12185-014-1731-7","article-title":"Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim","volume":"101","author":"Kuter","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0610","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-2141.1991.tb04467.x","article-title":"DAPSONE for idiopathic autoimmune thrombocytopenic purpura in elderly patients","volume":"78","author":"Durand","year":"1991","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0615","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/ajh.2830440117","article-title":"Dapsone for autoimmune thrombocytopenic purpura","volume":"44","author":"Godeau","year":"1993","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0620","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/ajh.22266","article-title":"Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab","volume":"87","author":"Zaja","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0625","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1046\/j.1365-2141.1997.412687.x","article-title":"Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases","volume":"97","author":"Godeau","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0630","doi-asserted-by":"crossref","first-page":"E201","DOI":"10.1002\/ajh.24068","article-title":"Cutaneous rash and dapsone-induced hypersensitivity syndrome a common manifestation in adult immune thrombocytopenia. Presentation and outcome in 16 cases","volume":"90","author":"Sauvetre","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0635","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/1076029615622002","article-title":"The effect of Danazol in primary immune thrombocytopenia: An analysis of a large cohort from a single center in China","volume":"22","author":"Liu","year":"2016","journal-title":"Clin Appl Thromb"},{"key":"10.1016\/j.ejim.2018.09.005_bb0640","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJM198306093082306","article-title":"Danazol for the treatment of idiopathic thrombocytopenic purpura","volume":"308","author":"Ahn","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2018.09.005_bb0645","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.amjmed.2003.12.024","article-title":"Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: Long-term results","volume":"116","author":"Maloisel","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2018.09.005_bb0650","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-107-2-177","article-title":"Low-dose danazol therapy in idiopathic thrombocytopenic purpura","volume":"107","author":"Ahn","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2018.09.005_bb0655","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.revmed.2015.08.007","article-title":"Is there still a place for \u2018old therapies\u2019 in the management of immune thrombocytopenia?","volume":"37","author":"Audia","year":"2016","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.ejim.2018.09.005_bb0660","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/jama.1967.03130170059006","article-title":"Azathioprine in refractory idiopathic thrombocytopenic purpura","volume":"202","author":"Sussman","year":"1967","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2018.09.005_bb0665","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bjh.13622","article-title":"Mycophenolate mofetil therapy for severe immune thrombocytopenia","volume":"171","author":"Taylor","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0670","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1046\/j.1365-2141.2001.02893.x","article-title":"Cyclosporin a for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy","volume":"114","author":"Kappers-Klunne","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0675","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ajh.23609","article-title":"Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies","volume":"89","author":"Khellaf","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0680","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/ejh.12586","article-title":"Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients","volume":"96","author":"Stirnemann","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ejim.2018.09.005_bb0685","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2257.2004.00643.x","article-title":"The use of vinca alkaloids in adult patients with refractory chronic idiopathic thrombocytopenia","volume":"26","author":"Sikorska","year":"2004","journal-title":"Clin Lab Haematol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620518303662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620518303662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:28:15Z","timestamp":1760606895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620518303662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":137,"alternative-id":["S0953620518303662"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2018.09.005","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of immune thrombocytopenia in elderly patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2018.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}